Clinical outcomes of patients with mitral prosthetic valve obstructive thrombosis treated with streptokinase or tenecteplase

Indian Heart Journal

P. Chandrasekhar¹  G. Ravi Kiran²  S. Mohammad Ali² 

[1] Corresponding author. Department of cardiology, Government general hospital, Kurnool, Andhra-pradesh, India.;Department of Cardiology, Kurnool Medical College and Hospital, Kurnool, India;

关键词: Prosthetic valve thrombosis;    Stuck valve;    Prosthetic valve;    Thrombolytic therapy;    Tenecteplase;    Streptokinase;   

DOI  :  

来源: DOAJ

【 摘 要 】

Agent of choice for thrombolytic therapy (TT) in prosthetic valve thrombosis (PVT) is unknown. 84 mitral obstructive-PVT episodes treated with TT (43: Tenecteplase; 41: Streptokinase) were included in this prospective study. The incidence of primary end-point (CCS: complete clinical success, defined as complete or partial hemodynamic success with no complications or surgery) was 84.5% with recurrent PVT as a sole predictor. Bleeding and embolic manifestations were noted in 8.3% and 4.7% of episodes respectively. Tenecteplase use was associated with lower complication rate and a mitral EOA of <0.74 cm2 at presentation predicts the need for extended thrombolysis (accuracy, 78.6%).

【 授权许可】

Unknown